NPSP Related FDA
-
NPS Pharma (NPSP) Regains Teduglutide Global Rights from Takeda
-
NPS Pharma (NPSP) Establishes Distribution Network for Gattex
-
Cramer Makes Solid Call on NPS Pharma (NPSP) into Gattex PDUFA
-
NPS Pharma (NPSP) Receives FDA Approval for Gattex
-
FDA approves NPS Pharmaceuticals' (NPSP) Gattex
-
NPS Pharmaceuticals (NPSP) Reports Publication of Encouraging Gattex Phase 3 Data
-
NPS Pharmaceuticals (NPSP) Mildly Higher after FDA Backing
-
NPS Pharmaceuticals (NPSP) to resume trading at 4:20PM
-
FDA panel backs NPS Pharmaceuticals (NPSP) Gattex
-
FDA Says NPS Pharma's (NPSP) Gattex has 'Clinically Meaningful' Benefit
-
NPS Pharma (NPSP) Halted Ahead of FDA Committee Meeting for Gattex
-
NPS Pharma (NPSP) Reports Significant Data from Natpara REPLACE Phase 3
-
NPS Pharmaceuticals (NPSP) On Watch With FDA Briefing Documents Posted
-
NPS Pharmaceuticals (NPSP) Jumps On Positive Analyst Comments Ahead of AdComm
-
NPS Pharma (NPSP) Higher as Cramer Highlights into UBS Conference
-
NPS Pharma (NPSP) to File BLA for Natpara in Mid-FY13
-
NPS Pharmaceuticals (NPSP) Gets FDA Committee Meeting Date for Gattex NDS; PDUFA in December
-
Jefferies Maintains a 'Buy' on NPS Pharmaceuticals (NPSP); 2012 Boston Healthcare Summit Update
-
FDA Needs More time to Review NPS Pharma's (NPSP) Gattex, Extends PDUFA Date to December FY12
-
Canaccord Genuity Maintains a 'Buy' on NPS Pharmaceuticals (NPSP); On the Shoulders of Gattex
-
Needham & Company Reiterates a 'Buy' on NPS Pharmaceuticals (NPSP); Gattex AdCom Meeting Tentatively Scheduled
-
Needham & Company Maintains a 'Buy' on NPS Pharmaceuticals (NPSP); Slight Gattex Delay Risk, Other Opportunities Underappreciated
-
NPS Pharma (NPSP) Amends Cinacalcet HCl Agreement with Amgen (AMGN); Acclerates Payments
-
NPS Pharmaceuticals (NPSP) Announces Amended Royalty Agreement with Amgen (AMGN)
-
Canaccord Genuity Maintains a 'Buy' on NPS Pharmaceuticals (NPSP); Highlights From Analyst Event
-
Needham & Company Reiterates a 'Buy' on NPS Pharmaceuticals (NPSP); Awaiting Date for Gattex FDA AdCom Meeting
-
Canaccord Genuity Reiterates a 'Buy' on NPS Pharmaceuticals (NPSP); Underappreciated Cumulative Value for GATTEX, NATPARA, and Sensipar Royalty
-
Needham & Company Reiterates a 'Buy' on NPS Pharmaceuticals (NPSP); Gattex PDUFA Date Announced, but FDA AdCom Timing Still Unknown
-
NPS Pharma's (NPSP) NDA for GATTEX Accepted by FDA
-
NPS Pharma (NPSP) announces FDA acceptance of NDA for Gattex(R) in adult SBS
-
NPS Pharmaceuticals (NPSP) Completes GATTEX NDA Submission to FDA
-
NPS Pharma (NPSP) Reports Positive REPLACE Data, Gets Orphan Drug Designation
-
NPS Pharma (NPSP) Submits CMC of NDA for GATTEX to U.S. FDA
-
NPS Pharma (NPSP) Submits Application to Market Teduglutide in Europe; Receives Milestone Payment
-
NPS Pharma (NPSP) Randomizes Last Patient in NPSP558 Phase 3
-
NPS Pharmaceuticals (NPSP) Phase 3 GATTEX Met Primary Efficacy Endpoint
-
NPS Pharma (NPSP) Completes STEPS; Advancing STEPS 2
-
NPS Pharmaceuticals (NPSP) Announces Positive Phase II NPSP558 Data
-
NPS Pharmaceuticals (NPSP) Receives FDA Letter Related to Generic Version of Company's Sensipar
-
NPS Pharmaceuticals (NPSP) Reports GATTEX Results, Said High Dose Did Not Reach Statistical Significance
-
NPS Pharma (NPSP) Falls After FDA Request New PREOS Trial
-
NPS Pharmaceuticals (NPSP) Tops Q1 EPS by 20c
-
NPS Phama (NPSP) Updates Status of PREOS NDA
-
Citigroup Highlights Biotech Day
-
UPDATE - NPSP Receives Approvable Letter
-
NPS Pharmaceuticals-NPSP March option implied volatility up to 125 into FDA action
-
NPSP to Advance Clinical Development of Teduglutide for Crohn's Disease
-
Citigroup Notes NPSP Preos PDUFA Date of March 10
-
NPSP Extends Strategic Alliance with AstraZeneca
-
NPSP Said Journal Reported Positive Trial Results
Back to NPSP Stock Lookup
